703 filings
Page 11 of 36
POS AM
tlx4sy
13 Mar 17
Prospectus update (post-effective amendment)
12:00am
POS AM
4vluod a2fy
13 Mar 17
Prospectus update (post-effective amendment)
12:00am
8-A12G/A
jrp o2nf7ff7697
7 Mar 17
Registration of securities (amended)
12:00am
8-K
drge 2owf
24 Feb 17
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
8je5jhcuh1lp
13 Jan 17
Departure of Directors or Certain Officers
12:00am
8-K
o6zg qnvaxqpooj
6 Jan 17
Departure of Directors or Certain Officers
12:00am
UPLOAD
6xtg4re11y p632
6 Jan 17
Letter from SEC
12:00am
8-K
651vsdgtwa
19 Dec 16
CytRx Appoints Chief Medical Officer Dr. Daniel Levitt as Chief Operating Officer
12:00am
424B5
wyqvez85 8w8dfp2
14 Dec 16
Prospectus supplement for primary offering
12:00am
424B5
q2jlo u2l
14 Dec 16
Prospectus supplement for primary offering
12:00am
8-K
125x5j49ycjw91 lik5
14 Dec 16
CytRx Corporation Announces $8.1 Million Registered Direct Offering of Common Stock
12:00am
8-K
iibxo9sbfjf8x
2 Dec 16
Leading Sarcoma Expert Dr. Earl W. Brien Joins CytRx Board of Directors
12:00am
8-K
j6ftu6y
29 Nov 16
CytRx Reports Statistically Significant Updated Results from Pivotal Phase 3 Trial of Aldoxorubicin in Patients with Second-Line Soft Tissue Sarcomas
12:00am
8-K
i1txejx ibsd
14 Nov 16
Unregistered Sales of Equity Securities
12:00am
8-K
78yc9jlb
9 Nov 16
CytRx Reports Third Quarter 2016 Financial Results
12:00am
8-K
eoia2eqf0f3uri2
19 Oct 16
Departure of Directors or Certain Officers
12:00am
8-K
pz4kaxghx o2x2ggt
26 Aug 16
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
S-8
swu87j
5 Aug 16
Registration of securities for employees
12:00am